During the recent session, Intellia Therapeutics Inc (NASDAQ:NTLA)’s traded shares were 0.99 million, with the beta value of the company hitting 1.80. At the last check today, the stock’s price was $10.66, reflecting an intraday loss of -3.18% or -$0.35. The 52-week high for the NTLA share is $34.87, that puts it down -227.11 from that peak though still a striking 13.23% gain since the share price plummeted to a 52-week low of $9.25. The company’s market capitalization is $1.09B, and the average intraday trading volume over the past 10 days was 3.64 million shares, and the average trade volume was 2.98 million shares over the past three months.
Intellia Therapeutics Inc (NTLA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. NTLA has a Sell rating from 0 analyst(s) out of 13 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 13 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.32.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
Intellia Therapeutics Inc (NTLA) registered a -3.18% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.18% in intraday trading to $10.66, hitting a weekly high. The stock’s 5-day price performance is 9.78%, and it has moved by -11.75% in 30 days. Based on these gigs, the overall price performance for the year is -59.20%. The short interest in Intellia Therapeutics Inc (NASDAQ:NTLA) is 21.67 million shares and it means that shorts have 9.35 day(s) to cover.
The consensus price target of analysts on Wall Street is $54, which implies an increase of 80.26% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $60 respectively. As a result, NTLA is trading at a discount of -462.85% off the target high and -68.86% off the low.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
Statistics show that Intellia Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Intellia Therapeutics Inc (NTLA) shares have gone down -59.71% during the last six months, with a year-to-date growth rate less than the industry average at 2.58% against 16.50. In the rating firms’ projections, revenue will increase 43.64% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.1M as predicted by 21 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 10.86M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled -1.92M and 28.93M respectively. In this case, analysts expect current quarter sales to grow by 522.52% and then drop by -62.47% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -22.30%. While earnings are projected to return 2.18% in 2025.
NTLA Dividends
Intellia Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Intellia Therapeutics Inc insiders own 1.19% of total outstanding shares while institutional holders control 92.08%, with the float percentage being 93.19%. ARK INVESTMENT MANAGEMENT LLC is the largest shareholder of the company, while 418.0 institutions own stock in it. As of 2024-06-30, the company held over 11.6 million shares (or 12.1419% of all shares), a total value of $259.51 million in shares.
The next largest institutional holding, with 9.6 million shares, is of BLACKROCK INC.’s that is approximately 10.0496% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $214.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of Intellia Therapeutics Inc (NTLA) shares are ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund. Data provided on Nov 30, 2024 indicates that ARK ETF Tr-ARK Innovation ETF owns about 8.76 shares. This amounts to just over 8.60 percent of the company’s overall shares, with a $94.57 million market value. The same data shows that the other fund manager holds slightly less at 3.17, or about 3.12% of the stock, which is worth about $34.27 million.
